# TCF21

## Overview
TCF21 is a gene that encodes the transcription factor 21, a basic helix-loop-helix (bHLH) protein involved in the regulation of various cellular processes. This transcription factor is pivotal in the differentiation of mesenchymal cells into smooth muscle cells and plays a significant role in organogenesis, particularly in the development of the heart, lungs, and kidneys (Ao2020TCF21:). TCF21 functions primarily within the nucleus, where it binds to E-box sequences in DNA to modulate the transcription of target genes, thereby influencing cellular activities such as proliferation, differentiation, and apoptosis (Ao2020TCF21:). The gene's expression and activity are crucial in the cardiovascular system, where it helps mitigate the risk of coronary artery disease by inhibiting the differentiation of coronary artery smooth muscle cells (Ao2020TCF21:). Additionally, TCF21 is essential for lung development, with its absence leading to conditions such as pulmonary hypoplasia (Park2019The). The gene's involvement in various signaling pathways underscores its importance in maintaining cellular homeostasis and its potential implications in disease pathogenesis.

## Structure


## Function
TCF21, a basic helix-loop-helix (bHLH) transcription factor, plays a crucial role in regulating various cellular processes in healthy human cells. It is involved in the differentiation of mesenchymal cells into smooth muscle cells and is essential for organogenesis, particularly in the heart, lungs, and kidneys (Ao2020TCF21:). TCF21 is active in the nucleus, where it binds to E-box sequences in DNA to regulate target gene transcription, influencing cellular processes such as proliferation, differentiation, and apoptosis (Ao2020TCF21:).

In the cardiovascular system, TCF21 inhibits the differentiation of human coronary artery smooth muscle cells, thereby reducing the risk of coronary artery disease (Ao2020TCF21:). It is also involved in the regulation of signaling pathways, including the PI3K/AKT and MAPK/ERK pathways, which are crucial for cell proliferation, differentiation, migration, and apoptosis (Ao2020TCF21:).

In the lungs, TCF21 is expressed in embryonic lung mesenchyme and is essential for lung development, as its absence leads to pulmonary hypoplasia (Park2019The). TCF21-expressing cells contribute to the formation of lipofibroblasts, which are important for lipid metabolism and surfactant production in the lungs (Park2019The).

## Clinical Significance
Mutations and alterations in the expression of the TCF21 gene have been implicated in several diseases, particularly cardiovascular diseases and cancers. In coronary artery disease (CAD), TCF21 is associated with the regulation of smooth muscle cell (SMC) phenotype, where it inhibits SMC differentiation by blocking the myocardin-serum response factor (MYOCD-SRF) pathway. This inhibition is linked to a protective role against CAD, as TCF21 promotes SMC de-differentiation, proliferation, and migration, which are crucial in the pathophysiology of atherosclerosis and restenosis after angioplasty (Luo2024Transcription; Nagao2020Coronary).

In cancer, TCF21 acts as a tumor suppressor gene. Its expression is often silenced through hypermethylation in lung and head and neck cancers, contributing to tumorigenesis. This epigenetic alteration leads to decreased TCF21 expression, which is associated with the progression of these cancers (Smith2006Epigenetic). Additionally, in gastric cancer, the polymorphism rs2327430 in TCF21 is linked to a favorable prognosis, as it modulates malignant behaviors by increasing TCF21 expression, affecting cell proliferation, migration, and apoptosis (Zhou2024Polymorphism).

Overall, TCF21's role in disease is complex, involving both protective and pathogenic mechanisms depending on the context and specific alterations in its expression or function.

## Interactions
TCF21 interacts with several proteins and nucleic acids, playing a significant role in coronary artery disease (CAD) and smooth muscle cell (SMC) differentiation. TCF21 is known to bind with JUN family transcription factors, including JUN and JUND, suggesting a cooperative role in regulating target genes. This interaction is supported by the significant overlap of TCF21 and JUN/JUND binding sites in human coronary artery smooth muscle cells (HCASMC) (Sazonova2015Characterization).

TCF21 also interacts with the myocardin-serum response factor (MYOCD-SRF) pathway, inhibiting the expression of SMC differentiation markers. TCF21 does not affect the expression levels of MYOCD or SRF but disrupts the MYOCD-SRF complex by directly interacting with MYOCD, as confirmed through immunoprecipitation assays (Nagao2020Coronary).

Additionally, TCF21 interacts with the aryl-hydrocarbon receptor (AHR) and ARNT, increasing their expression in HCASMC. This interaction suggests an overlap in the transcriptional networks of TCF21 and AHR, promoting the expression of inflammatory genes (Kim2017TCF21).

TCF21 also exhibits interactions with SMAD3, where it inhibits SMAD3 binding through an epigenetic mechanism affecting chromatin accessibility, indicating a mutual inhibitory interaction (Iyer2018Coronary).


## References


[1. (Kim2017TCF21) Juyong Brian Kim, Milos Pjanic, Trieu Nguyen, Clint L. Miller, Dharini Iyer, Boxiang Liu, Ting Wang, Olga Sazonova, Ivan Carcamo-Orive, Ljubica Perisic Matic, Lars Maegdefessel, Ulf Hedin, and Thomas Quertermous. Tcf21 and the environmental sensor aryl-hydrocarbon receptor cooperate to activate a pro-inflammatory gene expression program in coronary artery smooth muscle cells. PLOS Genetics, 13(5):e1006750, May 2017. URL: http://dx.doi.org/10.1371/journal.pgen.1006750, doi:10.1371/journal.pgen.1006750. This article has 55 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1006750)

[2. (Park2019The) Juwon Park, Malina J. Ivey, Yanik Deana, Kara L. Riggsbee, Emelie Sörensen, Veronika Schwabl, Caroline Sjöberg, Tilda Hjertberg, Ga Young Park, Jessica M. Swonger, Taylor Rosengreen, Rory E. Morty, Katrin Ahlbrecht, and Michelle D. Tallquist. The tcf21 lineage constitutes the lung lipofibroblast population. American Journal of Physiology-Lung Cellular and Molecular Physiology, 316(5):L872–L885, May 2019. URL: http://dx.doi.org/10.1152/ajplung.00254.2018, doi:10.1152/ajplung.00254.2018. This article has 61 citations.](https://doi.org/10.1152/ajplung.00254.2018)

[3. (Sazonova2015Characterization) Olga Sazonova, Yuqi Zhao, Sylvia Nürnberg, Clint Miller, Milos Pjanic, Victor G. Castano, Juyong B. Kim, Elias L. Salfati, Anshul B. Kundaje, Gill Bejerano, Themistocles Assimes, Xia Yang, and Thomas Quertermous. Characterization of tcf21 downstream target regions identifies a transcriptional network linking multiple independent coronary artery disease loci. PLOS Genetics, 11(5):e1005202, May 2015. URL: http://dx.doi.org/10.1371/journal.pgen.1005202, doi:10.1371/journal.pgen.1005202. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1005202)

[4. (Smith2006Epigenetic) Laura T. Smith, Mauting Lin, Romulo M. Brena, James C. Lang, David E. Schuller, Gregory A. Otterson, Carl D. Morrison, Dominic J. Smiraglia, and Christoph Plass. Epigenetic regulation of the tumor suppressor gene tcf21 on 6q23-q24 in lung and head and neck cancer. Proceedings of the National Academy of Sciences, 103(4):982–987, January 2006. URL: http://dx.doi.org/10.1073/pnas.0510171102, doi:10.1073/pnas.0510171102. This article has 127 citations.](https://doi.org/10.1073/pnas.0510171102)

[5. (Luo2024Transcription) Yaqian Luo, Fangzhou He, Yifang Zhang, Shufan Li, Ruirui Lu, Xing Wei, and Ji Huang. Transcription factor 21: a transcription factor that plays an important role in cardiovascular disease. Pharmacology, 109(4):183–193, 2024. URL: http://dx.doi.org/10.1159/000536585, doi:10.1159/000536585. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000536585)

[6. (Nagao2020Coronary) Manabu Nagao, Qing Lyu, Quanyi Zhao, Robert C. Wirka, Joetsaroop Bagga, Trieu Nguyen, Paul Cheng, Juyong Brian Kim, Milos Pjanic, Joseph M. Miano, and Thomas Quertermous. Coronary disease-associated gene tcf21 inhibits smooth muscle cell differentiation by blocking the myocardin-serum response factor pathway. Circulation Research, 126(4):517–529, February 2020. URL: http://dx.doi.org/10.1161/circresaha.119.315968, doi:10.1161/circresaha.119.315968. This article has 76 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/circresaha.119.315968)

[7. (Ao2020TCF21:) Xiang Ao, Wei Ding, Yuan Zhang, Dan Ding, and Ying Liu. Tcf21: a critical transcription factor in health and cancer. Journal of Molecular Medicine, 98(8):1055–1068, June 2020. URL: http://dx.doi.org/10.1007/s00109-020-01934-7, doi:10.1007/s00109-020-01934-7. This article has 32 citations.](https://doi.org/10.1007/s00109-020-01934-7)

[8. (Iyer2018Coronary) Dharini Iyer, Quanyi Zhao, Robert Wirka, Ameay Naravane, Trieu Nguyen, Boxiang Liu, Manabu Nagao, Paul Cheng, Clint L. Miller, Juyong Brian Kim, Milos Pjanic, and Thomas Quertermous. Coronary artery disease genes smad3 and tcf21 promote opposing interactive genetic programs that regulate smooth muscle cell differentiation and disease risk. PLOS Genetics, 14(10):e1007681, October 2018. URL: http://dx.doi.org/10.1371/journal.pgen.1007681, doi:10.1371/journal.pgen.1007681. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1007681)

[9. (Zhou2024Polymorphism) Xinyi Zhou, Kuan Shen, Shuqing Cao, Pengyu Li, Jian Xiao, Jiacheng Dong, Quan Cheng, Li Hu, Zekuan Xu, and Li Yang. Polymorphism rs2327430 in tcf21 predicts the risk and prognosis of gastric cancer by affecting the binding between tfap2a and tcf21. Cancer Cell International, May 2024. URL: http://dx.doi.org/10.1186/s12935-024-03343-z, doi:10.1186/s12935-024-03343-z. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-024-03343-z)